Definition and management of ruxolitinib treatment failure in myelofibrosis

ανά Pardanani, A, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2014)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience

ανά Begna, K, Abdelatif, A, Schwager, S, Hanson, C, Pardanani, A, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2016)

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

ανά Abdel-Wahab, O, Pardanani, A, Rampal, R, Lasho, TL, Levine, RL, Tefferi, A
Τόπος έκδοσης Leukemia (2011)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis

ανά Tefferi, A, Saeed, L, Hanson, C A, Ketterling, R P, Pardanani, A, Gangat, N
Τόπος έκδοσης Leukemia (2017)

Bortezomib therapy in myelofibrosis: a phase II clinical trial

ανά Mesa, RA, Verstovsek, S, Rivera, C, Pardanani, A, Hussein, K, Lasho, T, Wu, W, Tefferi, A
Τόπος έκδοσης Leukemia (2008)

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis

ανά Barraco, D, Lasho, T L, Gangat, N, Finke, C, Elala, Y C, Pardanani, A, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2016)

Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations

ανά Barraco, D, Cerquozzi, S, Hanson, C A, Ketterling, R P, Pardanani, A, Gangat, N, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2017)

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes

ανά Pardanani, A, Finke, C, Lasho, T L, Al-Kali, A, Begna, K H, Hanson, C A, Tefferi, A
Έκδοση 2012

Liver function test abnormalities and their clinical relevance in primary myelofibrosis

ανά Barraco, D, Mudireddy, M, Shah, S, Hanson, C A, Ketterling, R P, Gangat, N, Pardanani, A, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2017)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients

ανά Cerquozzi, S., Barraco, D., Lasho, T., Finke, C., Hanson, C. A., Ketterling, R. P., Pardanani, A., Gangat, N., Tefferi, A.
Τόπος έκδοσης Blood Cancer J (2017)

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

ανά Caramazza, D, Begna, K H, Gangat, N, Vaidya, R, Siragusa, S, Van Dyke, D L, Hanson, C, Pardanani, A, Tefferi, A
Έκδοση 2011

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

ανά Tefferi, A, Jimma, T, Sulai, N H, Lasho, T L, Finke, C M, Knudson, R A, McClure, R F, Pardanani, A
Έκδοση 2012

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

ανά Pardanani, A, Lasho, TL, Laborde, RR, Elliott, M, Hanson, CA, Knudson, RA, Ketterling, RP, Maxson, JE, Tyner, JW, Tefferi, A
Έκδοση 2013

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II c...

ανά Pardanani, A, Tefferi, A, Guglielmelli, P, Bogani, C, Bartalucci, N, Rodríguez, J, Extremera, S, Pérez, I, Alfaro, V, Vannucchi, A M
Τόπος έκδοσης Blood Cancer J (2015)

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

ανά Abdel-Wahab, O, Pardanani, A, Patel, J, Wadleigh, M, Lasho, T, Heguy, A, Beran, M, Gilliland, DG, Levine, RL, Tefferi, A
Τόπος έκδοσης Leukemia (2011)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia

ανά Lasho, T L, Finke, C M, Zblewski, D, Patnaik, M, Ketterling, R P, Chen, D, Hanson, C A, Tefferi, A, Pardanani, A
Τόπος έκδοσης Blood Cancer J (2015)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

ανά Pardanani, A, Tefferi, A, Jamieson, C, Gabrail, N Y, Lebedinsky, C, Gao, G, Liu, F, Xu, C, Cao, H, Talpaz, M
Τόπος έκδοσης Blood Cancer J (2015)

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

ανά Tefferi, A, Lim, K-H, Abdel-Wahab, O, Lasho, TL, Patel, J, Patnaik, MM, Hanson, CA, Pardanani, A, Gilliland, DG, Levine, RL
Τόπος έκδοσης Leukemia (2009)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML

ανά Laborde, R R, Patnaik, M M, Lasho, T L, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A
Έκδοση 2013

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

ανά Barraco, D, Elala, Y C, Lasho, T L, Begna, K H, Gangat, N, Finke, C, Hanson, C A, Ketterling, R P, Pardanani, A, Tefferi, A
Τόπος έκδοσης Blood Cancer J (2016)